Molecular Partners AG (MOLN), a clinical-stage biotechnology firm, is seeking emergency use authorization from the US FDA for ensovibep, a designed ankyrin repeat protein (DARPin) antiviral therapy candidate to treat COVID-19 through its partner. MOLN is working on DARPin therapies,…
Continue Reading